JAFFER A AJANI to Camptothecin
This is a "connection" page, showing publications JAFFER A AJANI has written about Camptothecin.
Connection Strength
2.672
-
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. Oncology. 2020; 98(5):289-294.
Score: 0.599
-
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. Invest New Drugs. 2005 Oct; 23(5):479-84.
Score: 0.221
-
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
Score: 0.201
-
Treatment of colorectal cancer metastasis: the role of chemotherapy. Cancer Metastasis Rev. 2004 Jan-Jun; 23(1-2):145-63.
Score: 0.196
-
Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):10-2.
Score: 0.191
-
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2.
Score: 0.191
-
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2002 May; 16(5 Suppl 5):16-8.
Score: 0.174
-
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002 Feb 01; 94(3):641-6.
Score: 0.171
-
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing? Oncology. 2022; 100(3):182-187.
Score: 0.169
-
Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs. 2001; 19(4):341-3.
Score: 0.159
-
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70.
Score: 0.066
-
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54.
Score: 0.056
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
Score: 0.051
-
Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg. 2004 Aug; 39(8):e8-10.
Score: 0.051
-
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398.
Score: 0.048
-
Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 5):52-4.
Score: 0.040
-
Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):34-7.
Score: 0.039
-
Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):44-7.
Score: 0.034
-
Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):692-9.
Score: 0.014